Senti Biosciences Enters Equity Commitment Letter With CPIF II-9 On Nov 9, 2026; CPIF II-9 To Purchase Up To $4.55M Of Senti Biosciences Common Stock

On November 9, 2026, Senti Biosciences Holdings, Inc., a Delaware corporation (the "Company"), entered into a new equity commitment letter (the "Equity Commitment Letter"), with CPIF II-9 Limited, an entity affiliated with Celadon Partners SPV 24 Limited (the "Investor"), pursuant to which, subject to the terms and conditions therein, the Investor agreed to purchase up to $4.55 million of shares of the Company’s common stock at a price per share equal to the "Minimum Price" as defined in Nasdaq Listing Rule 5635(d). At the Company's option, the commitment will be funded and settled quarterly, on or before the last day of each fiscal quarter of the Company (each, a "Settlement Date"). The scheduled amounts are: $1.8 million by December 31, 2026; $1.35 million by March 31, 2027; $0.5 million by June 30, 2027; $0.5 million by September 30, 2027; and $0.4 million by December 31, 2027. The number of shares purchased on each Settlement Date will equal the amount settled on that date divided by the per share price, rounded down to the nearest whole share.